注册号: Registration number: |
ChiCTR-IOR-17011733 |
最近更新日期: Date of Last Refreshed on: |
2017-06-21 |
注册时间: Date of Registration: |
2017-06-21 |
注册号状态: |
预注册 |
Registration Status: |
Prospective registration |
注册题目: |
氢吗啡酮通过调节HO-1表达改善线粒体动力学平衡从而减轻二氧化碳气腹肺损伤 |
Public title: |
Hydromorphine via HO-1 upregulation improves the balance of mitochondrial dynamics and alleviate CO2 pneumoperitoneum related lung injury |
注册题目简写: |
|
English Acronym: |
|
研究课题的正式科学名称: |
氢吗啡酮通过调节HO-1表达改善线粒体动力学平衡从而减轻二氧化碳气腹肺损伤 |
Scientific title: |
Hydromorphine via HO-1 upregulation improves the balance of mitochondrial dynamics and alleviate CO2 pneumoperitoneum related lung injury |
研究课题代号(代码): Study subject ID: |
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
申请注册联系人: |
史佳 |
研究负责人: |
余剑波 |
Applicant: |
Shi Jia |
Study leader: |
Yu Jianbo |
申请注册联系人电话: Applicant telephone: |
+86 13652033134 |
研究负责人电话: Study leader's telephone: |
+86 13652033134 |
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
申请注册联系人电子邮件: Applicant E-mail: |
steadysj@sina.com |
研究负责人电子邮件: Study leader's E-mail: |
yujianbo11@126.com |
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
申请注册联系人通讯地址: |
天津市南开区长江道6号 |
研究负责人通讯地址: |
天津市南开区长江道6号 |
Applicant address: |
6 Changjiang road, Nankai district, Tianjin, China |
Study leader's address: |
6 Changjiang road, Nankai district, Tianjin, China |
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
申请人所在单位: |
天津市南开医院麻醉科 |
||
Applicant's institution: |
Department of Anesthesiology, Tianjin Nankai Hospital |
是否获伦理委员会批准: |
是 |
||
Approved by ethic committee: |
Yes |
||
伦理委员会批件文号: Approved No. of ethic committee: |
2017-007P |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
批准本研究的伦理委员会名称: |
天津市南开医院伦理委员会 |
||
Name of the ethic committee: |
Ethic Committe of Tianjin Nankai Hospital |
||
伦理委员会批准日期: Date of approved by ethic committee: |
2017-02-24 | ||
伦理委员会联系人: |
|
||
Contact Name of the ethic committee: |
|
||
伦理委员会联系地址: |
|
||
Contact Address of the ethic committee: |
|
||
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
研究实施负责(组长)单位: |
天津市南开医院麻醉科 |
||||||||||||||||||||||
Primary sponsor: |
Department of Anesthesiology, Tianjin Nankai Hospital |
||||||||||||||||||||||
研究实施负责(组长)单位地址: |
天津市南开区长江道6号 |
||||||||||||||||||||||
Primary sponsor's address: |
6 Changjiang road, Nankai district, Tianjin, China |
||||||||||||||||||||||
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
经费或物资来源: |
自筹经费 |
||||||||||||||||||||||
Source(s) of funding: |
Self-financing |
||||||||||||||||||||||
研究疾病: |
经腹腔镜全子宫切除手术治疗的患者 |
||||||||||||||||||||||
Target disease: |
Patients undergoing laparoscopic total hysterectomy |
||||||||||||||||||||||
研究疾病代码: |
|
||||||||||||||||||||||
Target disease code: |
|
||||||||||||||||||||||
研究类型: |
干预性研究 |
||||||||||||||||||||||
Study type: |
Interventional study |
||||||||||||||||||||||
研究所处阶段: |
其它 | ||||||||||||||||||||||
Study phase: |
N/A |
||||||||||||||||||||||
研究目的: |
探讨氢吗啡酮通过调节HO-1表达改善线粒体动力学平衡从而减轻CO2气腹相关性肺损伤,为氢吗啡酮减轻CO2气腹相关性肺损伤提供理论依据,为氢吗啡酮的临床应用奠定基础 |
||||||||||||||||||||||
Objectives of Study: |
To test the hypothesis that hydromorphine via HO-1 upregulation improves the balance of mitochondrial dynamics and alleviate CO2 pneumoperitoneum related lung injury |
||||||||||||||||||||||
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
研究设计: |
随机平行对照 |
||||||||||||||||||||||
Study design: |
Parallel |
||||||||||||||||||||||
纳入标准: |
选取择期行全身麻醉下经腹腔镜全子宫切除手术治疗的女性患者,ASA I~II级,年龄在30-65岁,体重40-70kg,所有患者均无慢性疼痛病史、精神病史和长期服用镇痛类药物病史 |
||||||||||||||||||||||
Inclusion criteria |
Women aged 30-65 yearsweighed 40-70kg with ASA status I or II, scheduled for elective laparoscopic total hysterectomy of<3h duration at Tianjin Nankai hospital between June 2017 and March 2018 were enrolled in this study. All patients have no history of chronic pain, mental illness, and a long-term history of pain reliever. |
||||||||||||||||||||||
排除标准: |
既往有阿片类/NSAIDS药物应用史、哮喘病史、精神类疾病史、严重心肺疾病史、严重肝肾疾病史及手术时间>3h |
||||||||||||||||||||||
Exclusion criteria: |
Exclusion criteria included cardiovascular disease (hypertension, arrhythmia or myocardial ischaemia), haemodynamic instability (active bleeding, hypovolaemia or loss of body fluid), asthma or chronic obstructive pulmonary disease, allergy to the study drug and body mass index < 16 or > 30 kg/m2. |
研究实施时间: Study execute time: |
从From2017-02-24至To 2018-03-01 |
征募观察对象时间: Recruiting time: |
从From2017-06-26至To 2018-03-01 |
干预措施: Interventions: |
|
研究实施地点: Countries of recruitment and research settings: |
|
测量指标: Outcomes: |
|